While recent advances in the treatment of pancreatic ductal adenocarcinoma (PDAC) have improved median OS, PDAC remains highly lethal, with 5-year overall survival < 50% even for patients who undergo aggressive surgery and chemotherapy. DOC1021 is a cell-based immunotherapy derived from the full complement of autologous tumor antigens. It leverages p38MAPK and mTORC1 signaling cascades to initiate phenotypic cDC1-like skewing of monocyte-derived DC, generating downstream development of CD8⁺ tissue-homing, cytolytic memory effectors. Here we report extended survival results from a phase I study cohort in which patients with potentially resectable PDAC received DOC1021 after surgical resection and standard neoadjuvant/adjuvant therapy. To prepare DOC1021, patient monocyte-derived DC were loaded with autologous tumor lysate and amplified tumor mRNA extracted from resected tumor. After completion of adjuvant therapy, DOC1021 was administered biweekly via CT-guided injection near lymph nodes in the post-operative surgical bed in conjunction with weekly subcutaneous peg-IFN. Blood was collected before and ~5 weeks after DOC1021 administration to assess peripheral immune responses. Seven patients (median age: 58 years, range: 49–71) received DOC1021 after R0 (71%) or R1 resection (29%) and standard neoadjuvant and/or adjuvant therapy. At the time of analysis, 5 patients are alive, 3 of whom remain relapse-free. Two patients have reached or are approaching 5 years of post-operative survival, with three additional patients under active follow-up at approximately 22 to 44 months post-surgery. The most common DOC1021-related adverse events were mild flu-like symptoms, with no dose-limiting toxicities observed. Post-vaccination, patients exhibited upregulation of CD127⁺ memory precursor effector cells (MPECs) with additional upregulation of granzyme B and IFN-γ expression in circulating CD8⁺ and CD4⁺ cells, respectively. DOC1021 can be safely delivered after PDAC resection and standard perioperative therapy with increasingly encouraging survival outcomes. A second study arm evaluating vaccination post-surgery but prior to adjuvant therapy is now open and accruing.